Financhill
Sell
36

BLFS Quote, Financials, Valuation and Earnings

Last price:
$22.30
Seasonality move :
9.5%
Day range:
$21.48 - $22.28
52-week range:
$18.70 - $29.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.75x
P/B ratio:
2.94x
Volume:
284.7K
Avg. volume:
566.7K
1-year change:
3.27%
Market cap:
$1B
Revenue:
$82.3M
EPS (TTM):
-$0.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BLFS
BioLife Solutions
$22.2M -$0.04 -16.38% -98.33% $31.22
IVF
INVO Fertility
$1.6M -- -8.8% -- --
NMTC
NeuroOne Medical Technologies
$1.3M -- 120.4% -57.14% $1.45
NTRB
Nutriband
$665K -$0.13 59.2% -38.1% $13.00
NVNO
enVVeno Medical
-- -$0.34 -- -9.68% $12.50
SINT
SINTX Technologies
$725K -$0.71 94.97% -79.78% $30.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BLFS
BioLife Solutions
$21.78 $31.22 $1B -- $0.00 0% 12.75x
IVF
INVO Fertility
$1.68 -- $1.8M -- $0.00 0% 0.15x
NMTC
NeuroOne Medical Technologies
$0.62 $1.45 $31M -- $0.00 0% 3.22x
NTRB
Nutriband
$5.48 $13.00 $61.1M -- $0.00 0% 27.17x
NVNO
enVVeno Medical
$3.35 $12.50 $58.7M -- $0.00 0% 326.81x
SINT
SINTX Technologies
$2.69 $30.00 $6.7M -- $0.00 0% 2.58x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BLFS
BioLife Solutions
3.54% 2.284 1.19% 3.53x
IVF
INVO Fertility
65.97% 3.433 20.29% 0.05x
NMTC
NeuroOne Medical Technologies
-- -0.602 -- 0.93x
NTRB
Nutriband
1.68% 3.138 0.28% 4.65x
NVNO
enVVeno Medical
-- 0.246 -- --
SINT
SINTX Technologies
2.11% 0.321 1.98% 2.98x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BLFS
BioLife Solutions
$15.8M -$1.2M -2.93% -3.1% -5.09% $1.6M
IVF
INVO Fertility
$592.3K -$2.5M -313.33% -714.24% -1044.01% -$3.6M
NMTC
NeuroOne Medical Technologies
$771.1K -$2.7M -281.01% -281.01% -163.76% -$59.3K
NTRB
Nutriband
$191K -$1.4M -65.19% -69.58% -210.38% -$1.1M
NVNO
enVVeno Medical
-- -$5M -- -- -- -$4M
SINT
SINTX Technologies
$45K -$2.4M -177.02% -180.99% -783.16% -$1.4M

BioLife Solutions vs. Competitors

  • Which has Higher Returns BLFS or IVF?

    INVO Fertility has a net margin of -1.87% compared to BioLife Solutions's net margin of -1063.02%. BioLife Solutions's return on equity of -3.1% beat INVO Fertility's return on equity of -714.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions
    65.94% -$0.01 $365.6M
    IVF
    INVO Fertility
    36.18% -$12.53 $9.8M
  • What do Analysts Say About BLFS or IVF?

    BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand INVO Fertility has an analysts' consensus of -- which suggests that it could grow by 257.14%. Given that INVO Fertility has higher upside potential than BioLife Solutions, analysts believe INVO Fertility is more attractive than BioLife Solutions.

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions
    7 0 0
    IVF
    INVO Fertility
    0 0 0
  • Is BLFS or IVF More Risky?

    BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison INVO Fertility has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.267%.

  • Which is a Better Dividend Stock BLFS or IVF?

    BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. INVO Fertility pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or IVF?

    BioLife Solutions quarterly revenues are $23.9M, which are larger than INVO Fertility quarterly revenues of $1.6M. BioLife Solutions's net income of -$448K is higher than INVO Fertility's net income of -$17.4M. Notably, BioLife Solutions's price-to-earnings ratio is -- while INVO Fertility's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 0.15x for INVO Fertility. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions
    12.75x -- $23.9M -$448K
    IVF
    INVO Fertility
    0.15x -- $1.6M -$17.4M
  • Which has Higher Returns BLFS or NMTC?

    NeuroOne Medical Technologies has a net margin of -1.87% compared to BioLife Solutions's net margin of -163.76%. BioLife Solutions's return on equity of -3.1% beat NeuroOne Medical Technologies's return on equity of -281.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions
    65.94% -$0.01 $365.6M
    NMTC
    NeuroOne Medical Technologies
    55.61% -$0.07 $1.1M
  • What do Analysts Say About BLFS or NMTC?

    BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 132.78%. Given that NeuroOne Medical Technologies has higher upside potential than BioLife Solutions, analysts believe NeuroOne Medical Technologies is more attractive than BioLife Solutions.

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions
    7 0 0
    NMTC
    NeuroOne Medical Technologies
    1 0 0
  • Is BLFS or NMTC More Risky?

    BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.671%.

  • Which is a Better Dividend Stock BLFS or NMTC?

    BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or NMTC?

    BioLife Solutions quarterly revenues are $23.9M, which are larger than NeuroOne Medical Technologies quarterly revenues of $1.4M. BioLife Solutions's net income of -$448K is higher than NeuroOne Medical Technologies's net income of -$2.3M. Notably, BioLife Solutions's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 3.22x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions
    12.75x -- $23.9M -$448K
    NMTC
    NeuroOne Medical Technologies
    3.22x -- $1.4M -$2.3M
  • Which has Higher Returns BLFS or NTRB?

    Nutriband has a net margin of -1.87% compared to BioLife Solutions's net margin of -211%. BioLife Solutions's return on equity of -3.1% beat Nutriband's return on equity of -69.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions
    65.94% -$0.01 $365.6M
    NTRB
    Nutriband
    29.58% -$0.12 $11.4M
  • What do Analysts Say About BLFS or NTRB?

    BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 137.23%. Given that Nutriband has higher upside potential than BioLife Solutions, analysts believe Nutriband is more attractive than BioLife Solutions.

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions
    7 0 0
    NTRB
    Nutriband
    1 0 0
  • Is BLFS or NTRB More Risky?

    BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison Nutriband has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.545%.

  • Which is a Better Dividend Stock BLFS or NTRB?

    BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or NTRB?

    BioLife Solutions quarterly revenues are $23.9M, which are larger than Nutriband quarterly revenues of $645.8K. BioLife Solutions's net income of -$448K is higher than Nutriband's net income of -$1.4M. Notably, BioLife Solutions's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 27.17x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions
    12.75x -- $23.9M -$448K
    NTRB
    Nutriband
    27.17x -- $645.8K -$1.4M
  • Which has Higher Returns BLFS or NVNO?

    enVVeno Medical has a net margin of -1.87% compared to BioLife Solutions's net margin of --. BioLife Solutions's return on equity of -3.1% beat enVVeno Medical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions
    65.94% -$0.01 $365.6M
    NVNO
    enVVeno Medical
    -- -$0.22 --
  • What do Analysts Say About BLFS or NVNO?

    BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand enVVeno Medical has an analysts' consensus of $12.50 which suggests that it could grow by 273.13%. Given that enVVeno Medical has higher upside potential than BioLife Solutions, analysts believe enVVeno Medical is more attractive than BioLife Solutions.

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions
    7 0 0
    NVNO
    enVVeno Medical
    1 0 0
  • Is BLFS or NVNO More Risky?

    BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.726%.

  • Which is a Better Dividend Stock BLFS or NVNO?

    BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or NVNO?

    BioLife Solutions quarterly revenues are $23.9M, which are larger than enVVeno Medical quarterly revenues of --. BioLife Solutions's net income of -$448K is higher than enVVeno Medical's net income of -$4.5M. Notably, BioLife Solutions's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 326.81x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions
    12.75x -- $23.9M -$448K
    NVNO
    enVVeno Medical
    326.81x -- -- -$4.5M
  • Which has Higher Returns BLFS or SINT?

    SINTX Technologies has a net margin of -1.87% compared to BioLife Solutions's net margin of -787.63%. BioLife Solutions's return on equity of -3.1% beat SINTX Technologies's return on equity of -180.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions
    65.94% -$0.01 $365.6M
    SINT
    SINTX Technologies
    15.46% -$1.29 $6.2M
  • What do Analysts Say About BLFS or SINT?

    BioLife Solutions has a consensus price target of $31.22, signalling upside risk potential of 43.35%. On the other hand SINTX Technologies has an analysts' consensus of $30.00 which suggests that it could grow by 1015.24%. Given that SINTX Technologies has higher upside potential than BioLife Solutions, analysts believe SINTX Technologies is more attractive than BioLife Solutions.

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions
    7 0 0
    SINT
    SINTX Technologies
    1 1 0
  • Is BLFS or SINT More Risky?

    BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.937%.

  • Which is a Better Dividend Stock BLFS or SINT?

    BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or SINT?

    BioLife Solutions quarterly revenues are $23.9M, which are larger than SINTX Technologies quarterly revenues of $291K. BioLife Solutions's net income of -$448K is higher than SINTX Technologies's net income of -$2.3M. Notably, BioLife Solutions's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 12.75x versus 2.58x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions
    12.75x -- $23.9M -$448K
    SINT
    SINTX Technologies
    2.58x -- $291K -$2.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

How High Will Planet Labs Stock Go in 2025?
How High Will Planet Labs Stock Go in 2025?

Today we dive into Planet Labs (NYSE: PL), the satellite…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
55
SBET alert for May 27

SharpLink Gaming [SBET] is up 568.15% over the past day.

Buy
60
MRUS alert for May 27

Merus NV [MRUS] is down 4.24% over the past day.

Buy
57
RGC alert for May 27

Regencell Bioscience Holdings [RGC] is down 7.86% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock